Vis enkel innførsel

dc.contributor.authorHattrem, Magnus Nergård
dc.contributor.authorDille, Morten Johnsen
dc.contributor.authorSeternes, Tore
dc.contributor.authorEge, Thorfinn
dc.contributor.authorDraget, Kurt Ingar
dc.date.accessioned2018-03-09T13:16:07Z
dc.date.available2018-03-09T13:16:07Z
dc.date.created2017-06-12T20:30:06Z
dc.date.issued2017
dc.identifier.citationClinical pharmacology in drug development. 2017, 7 (2), 168-176.nb_NO
dc.identifier.issn2160-763X
dc.identifier.urihttp://hdl.handle.net/11250/2489850
dc.description.abstractThe first aim of the present study was to evaluate the bioavailability of ibuprofen dispersed in a novel soft chewable formulation compared with a traditional ibuprofen tablet; its second was to map the quality of taste masking and patient product satisfaction. In a phase 1, single-center, open-label, randomized, crossover study, healthy subjects received a soft-chew formulation or a hard tablet (reference), both containing 100 mg ibuprofen. Serial blood samples were collected over 24 hours to assess ibuprofen bioavailability. Taste and satisfaction after chewing the novel formulation 3 or 8 times were evaluated with a questionnaire. The soft-chew formulation showed comparable bioavailability to the reference tablet. The highest peak plasma concentration was observed after 3 chews, and the relative bioavailability was approximately 8% higher compared to 8 chews. The overall flavor was well appreciated, and chewing 3 times was significantly preferred (P = .043) over chewing 8 times. Soft chewable drug formulations may improve compliance and potentially benefit several subpopulations who experience dysphagia.nb_NO
dc.language.isoengnb_NO
dc.publisherWileynb_NO
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleThe Relative Bioavailability of Ibuprofen After Administration With a Novel Soft Chewable Drug Formulationnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber168-176nb_NO
dc.source.volume7nb_NO
dc.source.journalClinical pharmacology in drug developmentnb_NO
dc.source.issue2nb_NO
dc.identifier.doi10.1002/cpdd.357
dc.identifier.cristin1475531
dc.description.localcode© 2017, The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License.nb_NO
cristin.unitcode194,66,15,0
cristin.unitnameInstitutt for bioteknologi og matvitenskap
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal